Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Deuschle

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
MMW Fortschritte Der Medizin|January 13, 2006
[Diabetes in treatment with antipsychotic drugs: who is at risk]]M Deuschle
Pharmacopsychiatry|March 7, 2001
Benzodiazepine withdrawal-induced catatoniaM Deuschle, F Lederbogen
Fortschritte Der Neurologie-Psychiatrie|May 15, 2002
[Depression and cardiovascular disease: pathogenetic factors of the stress concept]M Deuschle, F Lederbogen
Der Nervenarzt|July 30, 2005
[Lengthening of QT interval by antipsychotic drugs]W Haverkamp, M Deuschle
Der Nervenarzt|October 17, 2012
[Depression and diabetes mellitus type 2]M Deuschle, U Schweiger
Pharmacopsychiatry|November 25, 2006
Dyskinesia during treatment with duloxetineM Deuschle, E Mase, M Zink
Der Internist|December 14, 1999
[Depression--a cardiovascular risk factor]F Lederbogen, M Deuschle, I Heuser
Fortschritte Der Neurologie-Psychiatrie|December 1, 2010
[The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data]G Paslakis, P Gass, M Deuschle
Der Internist|May 28, 2010
[Insomnia in the elderly. An under-diagnosed and over-treated syndrome]S Schwarz, L Frölich, M Deuschle
Medical Hypotheses|May 26, 2012
Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depressionG Paslakis, W F Blum, M Deuschle
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
MMW Fortschritte Der Medizin|January 13, 2006
[Diabetes in treatment with antipsychotic drugs: who is at risk]]M Deuschle
Pharmacopsychiatry|March 7, 2001
Benzodiazepine withdrawal-induced catatoniaM Deuschle, F Lederbogen
Fortschritte Der Neurologie-Psychiatrie|May 15, 2002
[Depression and cardiovascular disease: pathogenetic factors of the stress concept]M Deuschle, F Lederbogen
Der Nervenarzt|July 30, 2005
[Lengthening of QT interval by antipsychotic drugs]W Haverkamp, M Deuschle
Der Nervenarzt|October 17, 2012
[Depression and diabetes mellitus type 2]M Deuschle, U Schweiger
Pharmacopsychiatry|November 25, 2006
Dyskinesia during treatment with duloxetineM Deuschle, E Mase, M Zink
Der Internist|December 14, 1999
[Depression--a cardiovascular risk factor]F Lederbogen, M Deuschle, I Heuser
Fortschritte Der Neurologie-Psychiatrie|December 1, 2010
[The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data]G Paslakis, P Gass, M Deuschle
Der Internist|May 28, 2010
[Insomnia in the elderly. An under-diagnosed and over-treated syndrome]S Schwarz, L Frölich, M Deuschle
Medical Hypotheses|May 26, 2012
Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depressionG Paslakis, W F Blum, M Deuschle
Pageof 9